Therapeutic agent

Taurine

PreliminaryEvidence level
2Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Plasma levels inversely correlated with PASC severity. 1-3g/day raises levels. Mitochondrial + NF-kB rationale. Safe; may help energy/autonomic symptoms. Good mechanistic support, limited direct trials.

Clinical Trials

2 trial(s) registered

NCT IDTitlePhaseStatus
NCT06721949Taurine Supplementation in Long COVIDPhase 2Recruiting
NCT07682402Taurine Supplementation in Adolescents With Post-COVID ConditionPhase 1Not yet recruiting

Key Studies / References

  • See linked studies